Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.66 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918542 | 0.86 | OPRM1 (0.67) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL18867761 | 0.80 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL12283963 | 0.80 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL13151540 | 0.80 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL19880922 | 0.80 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 0.79 | OPRD1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13154676 | 0.79 | OPRD1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 0.79 | OPRD1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL10820235 | 0.79 | OPRD1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8049464 | 0.79 | OPRD1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424547-B1 | PACKAGING SYSTEM FOR OXYGEN-SENSITIVE DRUGS | FRESENIUS KABI AUSTRIA GMBH (AT) | 2026-02-11 | — | — | EP | disclosed |
| US-20200345720-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2020-11-05 | — | — | US | disclosed |
| EP-3424547-A1 | PACKAGING SYSTEM FOR OXYGEN-SENSITIVE DRUGS | Fresenius Kabi Austria GmbH (AT) | 2019-01-09 | — | — | EP | disclosed |
| EP-2968132-B1 | INJECTABLE MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-3143988-A1 | INJECTABLE MORPHINE FORMULATIONS | Fresenius Kabi Deutschland GmbH (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9192608-B2 | Morphine formulations | BECTON DICKINSON FRANCE S.A.S. (FR) | 2015-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345720-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.